Antibody-targeted photolysis: in vitro studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using a modified dextran carrier
- PMID: 1693435
- PMCID: PMC54079
- DOI: 10.1073/pnas.87.11.4217
Antibody-targeted photolysis: in vitro studies with Sn(IV) chlorin e6 covalently bound to monoclonal antibodies using a modified dextran carrier
Abstract
A monoclonal antibody-dextran-Sn(IV) chlorin e6 immunoconjugate was prepared by a technique involving the site-specific covalent modification of the monoclonal antibody oligosaccharide moiety. Dextran carriers were synthesized with a single chain-terminal hydrazide group, which was used as the coupling point between the carrier and the monoclonal antibody carbohydrate. Selective in vitro photolysis of SK-MEL-2 human malignant melanoma cells was accomplished using several conjugates prepared from anti-melanoma 2.1 (chromophore:antibody molar ratios, 6.8 and 11.2). Phototoxicity, as measured by clonogenic assay, was dependent on the delivered dose of 634-nm light and was observed only for conjugates that bound SK-MEL-2 cells. As judged by competitive inhibition radioimmunoassay, conjugates prepared in this fashion showed excellent retention of antigen binding activity relative to the unmodified antibody.
Similar articles
-
Antibody-targeted photolysis: in vitro immunological, photophysical, and cytotoxic properties of monoclonal antibody-dextran-Sn(IV) chlorin e6 immunoconjugates.Biotechnol Prog. 1992 Jan-Feb;8(1):30-9. doi: 10.1021/bp00013a006. Biotechnol Prog. 1992. PMID: 1371392
-
Antibody-targeted photolysis. Bacteriocidal effects of Sn (IV) chlorin e6-dextran-monoclonal antibody conjugates.Ann N Y Acad Sci. 1991;618:383-93. doi: 10.1111/j.1749-6632.1991.tb27258.x. Ann N Y Acad Sci. 1991. PMID: 1706578
-
Preparation and characterization of immunoconjugates for antibody-targeted photolysis.Bioconjug Chem. 1990 May-Jun;1(3):212-21. doi: 10.1021/bc00003a006. Bioconjug Chem. 1990. PMID: 1710935
-
Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends.Clin Pharmacokinet. 1992 Aug;23(2):85-9. doi: 10.2165/00003088-199223020-00001. Clin Pharmacokinet. 1992. PMID: 1511531 Review. No abstract available.
-
Drug-monoclonal antibody conjugates for cancer therapy: potentials and limitations.Crit Rev Ther Drug Carrier Syst. 1988;5(3):189-227. Crit Rev Ther Drug Carrier Syst. 1988. PMID: 3060267 Review.
Cited by
-
Photoimmunotherapy and biodistribution with an OC125-chlorin immunoconjugate in an in vivo murine ovarian cancer model.Br J Cancer. 1994 Sep;70(3):474-80. doi: 10.1038/bjc.1994.330. Br J Cancer. 1994. PMID: 8080733 Free PMC article.
-
A conjugate of an anti-midkine single-chain variable fragment to doxorubicin inhibits tumor growth.Braz J Med Biol Res. 2012 Mar;45(3):230-7. doi: 10.1590/s0100-879x2012007500009. Epub 2012 Jan 26. Braz J Med Biol Res. 2012. PMID: 22267001 Free PMC article.
-
Selective and effective killing of angiogenic vascular endothelial cells and cancer cells by targeting tissue factor using a factor VII-targeted photodynamic therapy for breast cancer.Breast Cancer Res Treat. 2011 Apr;126(3):589-600. doi: 10.1007/s10549-010-0957-1. Epub 2010 Jun 1. Breast Cancer Res Treat. 2011. PMID: 20514515 Free PMC article.
-
Leveraging synthetic chlorins for bio-imaging applications.Chem Commun (Camb). 2020 Oct 20;56(83):12608-12611. doi: 10.1039/d0cc05494a. Chem Commun (Camb). 2020. PMID: 32945820 Free PMC article.
-
Current status of photodynamic therapy in oncology.Drugs. 1994 Oct;48(4):510-27. doi: 10.2165/00003495-199448040-00003. Drugs. 1994. PMID: 7528127 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials